Pages that link to "Q24242946"
Jump to navigation
Jump to search
The following pages link to Targeted therapy for advanced renal cell carcinoma (Q24242946):
Displaying 45 items.
- Immunotherapy for metastatic renal cell carcinoma (Q24186688) (← links)
- Wnt Signaling in Renal Cell Carcinoma (Q26744312) (← links)
- Cytoreductive surgery in the era of targeted molecular therapy (Q26774134) (← links)
- The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy (Q26783291) (← links)
- Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities (Q26852437) (← links)
- Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib (Q28765488) (← links)
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (Q29618031) (← links)
- Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group (Q30486440) (← links)
- Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib (Q33387073) (← links)
- Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha (Q33847825) (← links)
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials (Q34032864) (← links)
- Renal cell carcinoma: molecular biology and targeted therapy (Q34513914) (← links)
- Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types (Q34669751) (← links)
- Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center (Q34775380) (← links)
- Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma (Q34995745) (← links)
- Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. (Q35205445) (← links)
- Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors (Q35580479) (← links)
- Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy (Q35584879) (← links)
- Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis (Q37253841) (← links)
- Sunitinib for advanced renal cell cancer (Q37307562) (← links)
- Optimizing recent advances in metastatic renal cell carcinoma (Q37428186) (← links)
- ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma (Q37588375) (← links)
- Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. (Q37671681) (← links)
- Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. (Q37687020) (← links)
- Multi-modal treatment for metastatic renal cancer: the role of surgery (Q37724029) (← links)
- Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis (Q38727698) (← links)
- Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma (Q38860651) (← links)
- Antiproliferative and apoptosis inducing effects of indirubin-3'-monoxime in renal cell cancer cells (Q39769686) (← links)
- State-of-the-art treatment of metastatic renal cell carcinoma. (Q39975802) (← links)
- Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites (Q40685017) (← links)
- Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma (Q41145898) (← links)
- Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma (Q41898172) (← links)
- Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor (Q42201994) (← links)
- Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial (Q42362967) (← links)
- Updates on novel therapies for metastatic renal cell carcinoma (Q42728990) (← links)
- Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. (Q45932398) (← links)
- Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma. (Q47282416) (← links)
- Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials (Q47358265) (← links)
- Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma. (Q52884927) (← links)
- Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape (Q57272360) (← links)
- Cepharanthine Enhances TRAIL-Mediated Apoptosis Through STAMBPL1-Mediated Downregulation of Survivin Expression in Renal Carcinoma Cells (Q58581294) (← links)
- [Renal cell carcinoma] (Q84752640) (← links)
- New Oral Anti-Cancer Drugs and Medication Safety (Q92532649) (← links)
- Targeted therapy for metastatic renal cell carcinoma (Q94337029) (← links)
- [Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer] (Q97067536) (← links)